EA201500836A1 - Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймера - Google Patents
Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймераInfo
- Publication number
- EA201500836A1 EA201500836A1 EA201500836A EA201500836A EA201500836A1 EA 201500836 A1 EA201500836 A1 EA 201500836A1 EA 201500836 A EA201500836 A EA 201500836A EA 201500836 A EA201500836 A EA 201500836A EA 201500836 A1 EA201500836 A1 EA 201500836A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- inhibitors
- helicase
- alzheimer
- primases
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 7
- 108060004795 Methyltransferase Proteins 0.000 title abstract 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102000016559 DNA Primase Human genes 0.000 abstract 2
- 108010092681 DNA Primase Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13154982 | 2013-02-12 | ||
| PCT/EP2014/052743 WO2014124978A2 (en) | 2013-02-12 | 2014-02-12 | Helicase-primase inhibitors for use in a method of treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201500836A1 true EA201500836A1 (ru) | 2016-02-29 |
Family
ID=47709982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201500836A EA201500836A1 (ru) | 2013-02-12 | 2014-02-12 | Ингибиторы хеликазы-примазы для применения в способе лечения болезни альцгеймера |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150374676A1 (enExample) |
| EP (1) | EP2956134A2 (enExample) |
| JP (1) | JP2016507546A (enExample) |
| KR (1) | KR20150119089A (enExample) |
| CN (1) | CN105101963A (enExample) |
| AU (1) | AU2014217962A1 (enExample) |
| BR (1) | BR112015019220A2 (enExample) |
| CA (1) | CA2898798A1 (enExample) |
| CL (1) | CL2015002241A1 (enExample) |
| EA (1) | EA201500836A1 (enExample) |
| IL (1) | IL240459A0 (enExample) |
| MX (1) | MX2015010339A (enExample) |
| PH (1) | PH12015501762A1 (enExample) |
| SG (1) | SG11201506153TA (enExample) |
| WO (1) | WO2014124978A2 (enExample) |
| ZA (1) | ZA201505243B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| ES2877854T3 (es) * | 2016-11-28 | 2021-11-17 | Aicuris Gmbh & Co Kg | Una sal de maleato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, procedimientos de fabricación y usos de las mismas para el tratamiento de los virus del herpes |
| TW202038947A (zh) * | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| KR102456699B1 (ko) | 2020-11-19 | 2022-10-19 | 주식회사 오에이티씨 | 디다노신을 포함하는 신경염증성 질환 예방 또는 치료용 조성물 |
| EP4580601A1 (en) * | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| US8299059B2 (en) * | 2009-10-30 | 2012-10-30 | Eli Lilly And Company | Crystalline compound and a process for its preparation |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
-
2014
- 2014-02-12 EP EP14703891.3A patent/EP2956134A2/en not_active Withdrawn
- 2014-02-12 WO PCT/EP2014/052743 patent/WO2014124978A2/en not_active Ceased
- 2014-02-12 SG SG11201506153TA patent/SG11201506153TA/en unknown
- 2014-02-12 KR KR1020157024625A patent/KR20150119089A/ko not_active Withdrawn
- 2014-02-12 AU AU2014217962A patent/AU2014217962A1/en not_active Abandoned
- 2014-02-12 CN CN201480008550.6A patent/CN105101963A/zh active Pending
- 2014-02-12 BR BR112015019220A patent/BR112015019220A2/pt not_active IP Right Cessation
- 2014-02-12 MX MX2015010339A patent/MX2015010339A/es unknown
- 2014-02-12 CA CA2898798A patent/CA2898798A1/en not_active Abandoned
- 2014-02-12 US US14/767,163 patent/US20150374676A1/en not_active Abandoned
- 2014-02-12 EA EA201500836A patent/EA201500836A1/ru unknown
- 2014-02-12 JP JP2015556537A patent/JP2016507546A/ja not_active Withdrawn
-
2015
- 2015-07-21 ZA ZA2015/05243A patent/ZA201505243B/en unknown
- 2015-08-09 IL IL240459A patent/IL240459A0/en unknown
- 2015-08-11 PH PH12015501762A patent/PH12015501762A1/en unknown
- 2015-08-11 CL CL2015002241A patent/CL2015002241A1/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
| US12285393B2 (en) | 2017-09-25 | 2025-04-29 | Qun Lu | Roles of modulators of intersectin-Cdc42 signaling in Alzheimer's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015501762A1 (en) | 2015-11-09 |
| ZA201505243B (en) | 2017-11-29 |
| WO2014124978A3 (en) | 2014-10-30 |
| AU2014217962A1 (en) | 2015-09-17 |
| BR112015019220A2 (pt) | 2017-07-18 |
| CL2015002241A1 (es) | 2016-02-19 |
| WO2014124978A4 (en) | 2014-12-24 |
| CA2898798A1 (en) | 2014-08-21 |
| MX2015010339A (es) | 2015-11-16 |
| EP2956134A2 (en) | 2015-12-23 |
| JP2016507546A (ja) | 2016-03-10 |
| US20150374676A1 (en) | 2015-12-31 |
| SG11201506153TA (en) | 2015-09-29 |
| IL240459A0 (en) | 2015-09-24 |
| WO2014124978A2 (en) | 2014-08-21 |
| KR20150119089A (ko) | 2015-10-23 |
| CN105101963A (zh) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691354A1 (ru) | Терапевтические ингибирующие соединения | |
| EA201690898A1 (ru) | Способы лечения таупатии | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| EP3777830C0 (en) | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF DRY EYE DISEASE | |
| EP3684418C0 (en) | COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE-RESPONSIVE DISORDERS | |
| EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
| EA201790789A1 (ru) | Композиции и способы, предназначенные для ингибирования экспрессии гена hao1 (оксидазы 1 гидроксикислот (гликолат-оксидазы)) | |
| EA201790413A1 (ru) | Антитела против tigit | |
| MX392098B (es) | Anticuerpos neutralizantes de poliomavirus. | |
| EA201690212A8 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| MX2022015248A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| PH12015501762A1 (en) | Helicase-primase inhibitors for use in a method of treating alzheimer's disease | |
| EP3500278C0 (en) | COMPOSITIONS FOR THE TREATMENT OF CONDITIONS USING A SELF-COMPLEMENTARY RECOMBINANT ADENO-ASSOCIATED VIRUS | |
| HUE053968T2 (hu) | Triazinon vázzal és imidazo-pirazinon vázzal rendelkezõ PDE9 inhibitorok perifériás betegségek kezelésére | |
| EP3359521C0 (en) | NEW COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | |
| EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
| EP2967900A4 (en) | INTERMEDIATE CAGE AND METHOD FOR TREATING SWIVELS WITH AN INTERMEDIATE CAGE | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| EP3256461C0 (en) | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN DDX3 HELICASE INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
| EP3585786C0 (en) | COMPOUNDS FOR THE TREATMENT OF GLYCOGEN STORAGE DISORDERS | |
| EP3523281A4 (en) | AUTOPHAGIC RIVER AND PHOSPHOLIPASE D ACTIVATORS AND PROTEIN UNIT CLEANING INCLUDING DEW AND TREATMENT OF PROTEINOPATHIA |